Ysios Capital launches InceptionBio: €100m for Spanish biotech spinouts

Ysios Capital, a transatlantic life sciences investor with offices in San Sebastián and Barcelona, launched the fund which will prioritise technology transfer from universities and research centres. It aims to create at least three new biotechs in 2026. It also scouts international assets for Spanish development, positioning the country as a biotech hub while complementing Ysios’ advisory role for Telescope Biotech Fund. A first closing secured backing from Spain’s CDTI (Centro para el Desarrollo Tecnológico y la Innovación), the government agency driving technological development and innovation, through its SICC Innvierte programme. This public vehicle co-invests in high-potential ventures alongside private capital, fostering tech transfer and startup growth in strategic sectors like biotech.

Managing Partner Joan Perell and Partner Arturo Urrios lead the effort, citing Spain’s world-class science as ripe for global impact. “Spain has world-class science and a unique opportunity to translate that science into globally impactful biotech companies. With InceptionBio, we aim to further strengthen our ability to engage at the earliest stages of innovation, working closely with the scientific ecosystem to build companies that can deliver meaningful solutions for patients,” said Joan Perelló.

Since 2008, Ysios Capital has backed 40+ biotechs, achieving six Nasdaq IPOs and ten M&As, including TiGenix’s €450m acquisition by Takeda and Sanifit’s €375m Vifor deal.